Navigation Links
Catalent Expert to Discuss the Importance of Formulation to Benefit Diabetes Patients at NLS Days
Date:9/4/2019

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that Rob Harris, Ph.D., Director, Science & Technology will present at the upcoming Nordic Life Science Days (NLS Days) conference, being held at the MalmöMässan Exhibition & Congress Center, Malmö, Sweden on Sept. 10-12, 2019.

On Thursday, Sept. 12 at 8:45 a.m., Dr. Harris will participate in the “Digitalization for the Benefit of the Diabetes Patient” panel session. The panelists will present different perspectives of how diabetes patients can benefit from recent digital advancements including viewpoints from the pharmaceutical industry, digitalization experts, and patient support groups. Dr. Harris will discuss the importance of formulation to overcome drug factors such as poor solubility and patient factors, including pill fatigue from the burden of multiple daily doses. He will also explain ways in which formulators can work with device developers on complex drug products to improve patient outcomes.

Ahead of NLS Days, on Tuesday, Sept. 10, Catalent will host a workshop, titled “Setting up your Drug for Clinical Success: Strategies and Considerations from Discovery to Clinic”. The day-long event will include expert speakers from Catalent and the wider pharmaceutical industry, and will focus on the key considerations for transitioning a molecule from discovery through to clinical studies. For more information, please visit: catalentmalmo.com.

Dr. Harris has over 35 years’ experience in the pharmaceutical industry. He started his career in technical support roles with R.P. Scherer, Warner Lambert and Glaxo Wellcome, before spending time in academia as a Research Fellow at the University of Manchester. For the past 15 years, Dr. Harris has worked in the pharmaceutical contract development and manufacturing sector, holding senior technical roles with Quay Pharma, Capsugel, Penn Pharma and Juniper Pharma Services (now part of Catalent). He has overseen the development of numerous new drug candidates for clinical evaluation and maintains a keen interest in technologies for enhancing oral bioavailability for challenging compounds, and the development of pediatric medicines.

To arrange a meeting with any of the attending Catalent experts at the event, contact Richard Kerns at NEPR - richard(at)nepr(dot)agency.

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including approximately 2,400 scientists, at more than 30 facilities across five continents, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Read the full story at https://www.prweb.com/releases/catalent_expert_to_discuss_the_importance_of_formulation_to_benefit_diabetes_patients_at_nls_days/prweb16543980.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Catalent Biologics Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy
2. IVERIC bio Enters into Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy for Orphan Inherited Retinal Diseases
3. Patient-Focused Drug Delivery to be Presented by Catalent at PODD
4. Lipid-Based Drug Delivery in Modern Pharmaceutical Development to be Presented by Catalent and BASF at Forthcoming Workshop
5. Catalent Biologics Announces Collaboration with Therachon, Switzerland, to Advance Clinical Development of Innovative Protein Therapy for Achondroplasia
6. Catalent Executives to Present on Clinical Trial Supply Management and Optimizing Product Development at Upcoming BioPharma Asia Conference
7. Portages Biohaven enters into exclusive formulation agreement and global license with Catalent for lead product
8. Cold Chain Experts Modality Solutions Recognized as an Inc. Verified Company
9. Lauren Bronich-Hall, Senior Quality Management Expert, Joins NDA Partners as an Expert Consultant
10. Process Characterization Expert Dr. Philippe Cini to Moderate Session at ISPE
11. October is Non-GMO Month – Industry Expert David Carter Available for Comment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/24/2019)... , ... September 24, 2019 ... ... of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene ... clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
(Date:9/22/2019)... BEAVERTON, Ore. (PRWEB) , ... September 20, 2019 ... ... the commercial launch of Brain-Derived Neurotrophic Factor (BDNF) testing in serum . ... peripheral nervous systems. BDNF stimulates the growth and differentiation of new neurons in ...
(Date:9/17/2019)... ... ... Jennifer Hermansky and Fang Xie, Ph.D. , attorneys from ... Rising Stars. Hermansky and Xie, named an Immigration Rising Star and a Life Sciences ... areas. The list highlights attorneys “whose legal accomplishments transcend their age,” according to Law360. ...
(Date:9/11/2019)... ... September 09, 2019 , ... Tunnell Consulting, ... agencies, announced that its president and CEO Maryann Gallivan has been accepted into ... The Forbes Council accepted Gallivan based on the role she and Tunnell ...
Breaking Biology Technology:
(Date:9/25/2019)... ... September 25, 2019 , ... ... through off-the-record collaboration and dialogue, today announces its inaugural South CEO ... Center in Louisiana. , Co-produced by Tulane University, this invitation-only meeting convenes ...
(Date:9/24/2019)... ... 2019 , ... HT Medical today announced a ... with the expansion of its proprietary Ti3D® spinal interbody cages. Through this launch, ... cervical and lumbar instrumentation sets available for surgical use. , The additional Ti3D ...
(Date:9/22/2019)... ... September 20, 2019 , ... ... adjusting to client demands for precision medicine products. The report, Lab Instrumentation ... billion in 2018, the pharma/bio sector is the largest source of demand for ...
Breaking Biology News(10 mins):